JPWO2020018503A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018503A5 JPWO2020018503A5 JP2021502424A JP2021502424A JPWO2020018503A5 JP WO2020018503 A5 JPWO2020018503 A5 JP WO2020018503A5 JP 2021502424 A JP2021502424 A JP 2021502424A JP 2021502424 A JP2021502424 A JP 2021502424A JP WO2020018503 A5 JPWO2020018503 A5 JP WO2020018503A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 334
- 108060003951 Immunoglobulin Proteins 0.000 claims description 107
- 102000018358 immunoglobulin Human genes 0.000 claims description 107
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 52
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 52
- 102000025171 antigen binding proteins Human genes 0.000 claims description 43
- 108091000831 antigen binding proteins Proteins 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 14
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 10
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 229940099539 IL-36 receptor antagonist Drugs 0.000 claims description 4
- 229960003697 abatacept Drugs 0.000 claims description 4
- -1 abatacept Substances 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 208000019028 Epidermal thickening Diseases 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 239000004012 Tofacitinib Substances 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 208000037883 airway inflammation Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950003468 dupilumab Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 102000057041 human TNF Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229960005435 ixekizumab Drugs 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000009928 nephrosis Diseases 0.000 claims description 2
- 231100001027 nephrosis Toxicity 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 229960004540 secukinumab Drugs 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 72
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010014199 Eczema infected Diseases 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000031455 DITRA Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 101001040964 Homo sapiens Interleukin-36 receptor antagonist protein Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 1
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 1
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 1
- 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 1
- 201000004290 Kindler syndrome Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 208000023368 generalized pustular psoriasis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000007798 pustular psoriasis 14 Diseases 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862698482P | 2018-07-16 | 2018-07-16 | |
| US62/698,482 | 2018-07-16 | ||
| US201962846989P | 2019-05-13 | 2019-05-13 | |
| US62/846,989 | 2019-05-13 | ||
| US201962866028P | 2019-06-25 | 2019-06-25 | |
| US62/866,028 | 2019-06-25 | ||
| PCT/US2019/041952 WO2020018503A2 (fr) | 2018-07-16 | 2019-07-16 | Anticorps anti-il36r |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530229A JP2021530229A (ja) | 2021-11-11 |
| JPWO2020018503A5 true JPWO2020018503A5 (fr) | 2022-06-13 |
| JP7386224B2 JP7386224B2 (ja) | 2023-11-24 |
Family
ID=67480435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502424A Active JP7386224B2 (ja) | 2018-07-16 | 2019-07-16 | 抗ｉｌ３６ｒ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11267893B2 (fr) |
| EP (1) | EP3823989A2 (fr) |
| JP (1) | JP7386224B2 (fr) |
| KR (1) | KR20210032401A (fr) |
| CN (1) | CN112513091A (fr) |
| AU (1) | AU2019306217B2 (fr) |
| BR (1) | BR112020027015A2 (fr) |
| CA (1) | CA3103531A1 (fr) |
| IL (1) | IL280013A (fr) |
| MX (1) | MX2021000566A (fr) |
| PH (1) | PH12020552178A1 (fr) |
| SG (1) | SG11202012360YA (fr) |
| WO (1) | WO2020018503A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016248208B2 (en) | 2015-04-15 | 2022-03-24 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
| AU2021319103A1 (en) | 2020-07-30 | 2023-02-09 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis |
| WO2022026829A1 (fr) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée |
| CN116685605A (zh) * | 2020-12-17 | 2023-09-01 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
| WO2022150644A1 (fr) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r) |
| WO2022150642A1 (fr) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Thérapie anti-récepteur de l'interleukine 36 (il-36r) contre la maladie de verneuil |
| WO2022166977A1 (fr) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | Anticorps anti-il-36r humain et son application |
| EP4301409A1 (fr) * | 2021-03-04 | 2024-01-10 | Boehringer Ingelheim International GmbH | Procédés de traitement du ppg |
| WO2022192531A2 (fr) | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarqueurs associés au traitement par anticorps anti-il-36 r dans le psoriasis pustuleux généralisé |
| AU2022291974A1 (en) * | 2021-06-18 | 2024-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-il-36r antibody and use thereof |
| WO2023285362A1 (fr) * | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'inhibiteurs d'il-36 permettant le traitement du syndrome de netherton |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (fr) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques |
| CA2199609A1 (fr) | 1994-09-09 | 1996-03-14 | Errol B. Desouza | Recepteurs de type 3 de l'interleukine 1 |
| US6239268B1 (en) | 1994-09-09 | 2001-05-29 | Neurocrine Biosciences, Inc. | Interleukin-1 type 3 receptors |
| US6326472B1 (en) | 1997-10-15 | 2001-12-04 | Schering Corporation | Human receptor proteins; related reagents and methods |
| WO1999019480A2 (fr) | 1997-10-15 | 1999-04-22 | Schering Corporation | Proteines receptrices humaines et reactifs et methodes associes |
| US20060003323A1 (en) | 2000-03-01 | 2006-01-05 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6900016B1 (en) | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030170630A1 (en) | 2000-12-21 | 2003-09-11 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| EP1729930A2 (fr) | 2004-04-01 | 2006-12-13 | Sequenom, Inc. | Procedes d'identification de risque d'osteoarthrite et traitements correspondants |
| WO2005108415A2 (fr) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Molecules associees aux membranes |
| WO2007047796A2 (fr) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA2852994C (fr) | 2011-11-16 | 2023-02-14 | Boehringer Ingelheim International Gmbh | Anticorps anti-il-36r |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| WO2014144666A2 (fr) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Procédés et compositions associés à l'activité des lymphocytes t |
| AU2016248208B2 (en) * | 2015-04-15 | 2022-03-24 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
| EP3601350A1 (fr) * | 2017-03-27 | 2020-02-05 | Boehringer Ingelheim International GmbH | Polythérapie à base d'anticorps anti il-36r |
-
2019
- 2019-07-16 SG SG11202012360YA patent/SG11202012360YA/en unknown
- 2019-07-16 CN CN201980050334.0A patent/CN112513091A/zh active Pending
- 2019-07-16 CA CA3103531A patent/CA3103531A1/fr active Pending
- 2019-07-16 BR BR112020027015-6A patent/BR112020027015A2/pt unknown
- 2019-07-16 EP EP19746372.2A patent/EP3823989A2/fr active Pending
- 2019-07-16 MX MX2021000566A patent/MX2021000566A/es unknown
- 2019-07-16 US US16/512,886 patent/US11267893B2/en active Active
- 2019-07-16 KR KR1020217002970A patent/KR20210032401A/ko unknown
- 2019-07-16 JP JP2021502424A patent/JP7386224B2/ja active Active
- 2019-07-16 WO PCT/US2019/041952 patent/WO2020018503A2/fr unknown
- 2019-07-16 AU AU2019306217A patent/AU2019306217B2/en active Active
-
2020
- 2020-12-15 PH PH12020552178A patent/PH12020552178A1/en unknown
-
2021
- 2021-01-07 IL IL280013A patent/IL280013A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7386224B2 (ja) | 抗ｉｌ３６ｒ抗体 | |
| US5639455A (en) | Immunosuppressant | |
| KR101625961B1 (ko) | 인터루킨-13 결합 단백질 | |
| RU2264413C2 (ru) | РЕКОМБИНАНТНОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ 1β | |
| US20200010571A1 (en) | Bispecific Anti-TNF-Alpha/IL-17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| JP6825033B2 (ja) | Ｂａｆｆ及びｂ７ｒｐ１に特異的なタンパク質及びその使用 | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| CA2778864C (fr) | Anticorps humanises contre il-22ra humain | |
| TWI482630B (zh) | 抗人類ｔｗｅａｋ抗體及其用途 | |
| KR20150038556A (ko) | ＴＮＦ-α 결합 단백질 | |
| KR20140018299A (ko) | Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법 | |
| EP2516467A2 (fr) | Compositions comprenant des antagonistes de tnf-alpha et il-6 et leurs procédés d'utilisation | |
| JPWO2020018503A5 (fr) | ||
| CN117402244A (zh) | Btla激动剂抗体及其用途 | |
| AU2016293391B2 (en) | Humanized anti-S100A9 antibody and uses thereof | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| JP2022522815A (ja) | Ｔｓｇ－６抗体およびその用途 | |
| WO2019148405A1 (fr) | ANTICORPS D'IL-4Rα ET SON UTILISATION | |
| JP7214921B2 (ja) | ヒト化抗ｉｌ１７ａ抗体及びその使用 | |
| WO2016070769A1 (fr) | Protéine de fusion recombinante pour le blocage simultané des voies de signalisation b7/cd28 et il6/il6r/gp130 | |
| EP4357361A1 (fr) | Anticorps anti-il-36r et son utilisation | |
| CN112513078B (zh) | 抗il-17a抗体及其用途 | |
| TW202144425A (zh) | 特異性抗原結合分子，其製備方法及醫藥用途 | |
| TW201321406A (zh) | 腫瘤壞死因子抗體及使用其之方法 |